Gender differences in clinical presentation and prognosis of thyroid eye disease. Issue 5 (September 2021)

• Record Type: Journal Article
• Authors: Zloto, Ofira; Sagiv, Oded; Priel, Ayelet; Cukierman-Yaffe, Tali; Tirosh, Amir; Agmon-Levin, Nancy; Madgar, Shiran; Serlin, Tal; Ben Simon, Guy
• Is Part Of: European journal of ophthalmology. Volume 31:Issue 5(2021)
• Page Start: 2717
• Page End: 2723
• Publication Date: 2021-09
• Subjects: Thyroid eye disease -- orbital disease -- eyelid disease: eyelid malpositions/trichiasis/ptosis -- strabismus -- optic neuropathy -- neuro ophthalmology; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; 617.7005
• DOI: 10.1177/1120672120964112
• Languages: English
• ISSNs: 1120-6721

Abstract

Objective: To examine the clinical differences in manifestation, treatment, and prognosis of thyroid-eye-disease (TED) between men and women. Methods: This is a longitudinal cohort study. Men and women, who diagnosed with TED and treated at a multidisciplinary TED clinic, were compared regarding differences in demographics, eye examination, disease activity, and quality of life evaluation. Results: TED was diagnosed in 132 patients during the study period, and they included 38 men (28.78%) and 94 women (71.21%). There were six men and 20 women with active disease (Clinical-Activity-Score (CAS) ⩾ 3) during the entire follow-up period ( p < 0.01). The mean time from TED diagnosis to CAS ⩾ 3 was 4.50 years for men and 2.35 years for women ( p = 0.05). There were no significant differences in mean total Graves' Orbitopathy-Quality-of-Life questionnaire (GO-QOL) score. However, mean GO-QOL subtotal score of external appearance of women was significantly lower compare to men in the first and last visit ( p = 0.04, 0.03, respectively). Conclusion: Active disease was more common in women and the time-from-diagnosis of TED to CAS ⩾ 3 was shorter among women. Moreover, the appearance QOL score of women was poorer. These findings should be taken into consideration when planning the timing of treatment and when choosing the best treatment for TED patients.